Kallistatin is known to play an important role in prevention of cancer, probably through its anti-angiogenic effects 5. The human body can therefore up-regulate kallistatin expression when cancers occur in a self-protective mechanism. In agreement with data in our present study, previous examination of plasma kallistatin concentrations detected 22.1��3.5??g/mL in 30 normal subjects and 21.1��3.8??g/mL in five patients with hereditary angioedema 7. check details
A significant decrease in kallistatin levels (7.2��2.5??g/mL, P<0.001) was also found in plasma samples from nine patients with liver disease 7. Such a discrepancy may be related to differences in the populations studied or may reflect the relatively small sample size. We have previously demonstrated that transgenic expression of kallistatin can significantly attenuate carbon tetrachloride-induced liver damage 37. This anti-inflammatory, <a href="https://en.wikipedia.org/wiki/Chloramben
">Chloramben anti-fibrotic potential of kallistatin warrants clinical evaluation, either with gene-therapy-based or recombinant-protein-administration-based evaluation of its therapeutic potential in human LC. Previous studies showed that other clinical situations can also affect serum kallistatin levels, such as adiposity, community-acquired pneumonia (CAP) and type 1 diabetes38?and?39. Serum kallistatin levels were significantly increased in diabetic vs. non-diabetic control subjects (12.6��4.2 vs. 10.3��2.8?��g/mL), and showing that levels were higher in diabetic www.selleckchem.com/screening/chemical-library.html
patients with complications but did not differ for complication-free patients 38. A study of CAP assessing the correlations of kallistatin with other biomarkers found that kallistatin was significantly consumed in CAP patients (median: 8.3, range 1.3�C17.3?��g/mL) compared with healthy subjects (median: 17.2, range 5.3-82.7?��g/mL) 39. These studies emphasize the diagnostic value of serum kallistatin levels in human LC, even though CAP patients have lower serum kallistatin levels, and the downgrading is fairly modest. However, the levels were decreased in liver disease but increased in diabetic patients. Therefore, comprehensive evaluation of kallistatin level and patients with obesity and diabetes history may determine their liver health more accurately. In conclusion, the present study demonstrated the levels of serum kallistatin reduced significantly in patients with LC of different etiologies, but not with HCC. The magnitude of this decrease appeared to be correlated with the degree of LC and disruption of normal liver function. Kallistatin therefore has a potential as a new biomarker for the diagnosis of, and evaluation of the extent of human LC, along with its response to therapeutic intervention. Furthermore, kallistatin may provide a new therapeutic strategy for the management and treatment of cirrhotic liver damage. This work was supported by the National Natural Science Foundation of China, China (Nos.